Company Overview and News


Add XLRN
to your dashboard

Headline News

Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195

2017-11-16 accesswire
LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Loxo Oncology, Inc. (NASDAQ: LOXO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=LOXO. The Company announced on November 14, 2017, that it has entered into a license, development, and commercialization agreement with Bayer Consumer Care AG wherein both the Companies will develop and commercialize Larotrectinib and LOXO-195 for the treatment of patients with TRK fusion cancers. (30-0)

XLRN / Acceleron Pharma Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-09 fintel.io
Acceleron Pharma Inc. (NASDAQ:XLRN) has 139 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 41,531,256 shares. Largest shareholders include Celgene Corp /de/, FMR LLC / Fidelity Management & Research, BlackRock Inc., Price T Rowe Associates Inc /md/, and Vanguard Group Inc. (90-0)

Acceleron Pharma's (XLRN) CEO Habib Dable on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Good day, ladies and gentlemen, and welcome to the Acceleron Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference is being recorded. (2-0)

Options Traders Expect Huge Moves in Acceleron Pharma (XLRN) Stock

2017-10-18 zacks
Investors in Acceleron Pharma Inc. (XLRN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 20th 2017 $50.00 Put had some of the highest implied volatility of all equity options today. (7-0)

Novo A/S - Current Holdings - Fintel.io

2017-10-13 fintel.io
Novo A/S has disclosed 20 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,050,041,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Novo A/S's top holdings are Inogen, Inc. (NASDAQ:INGN) , AnaptysBio, Inc. (NASDAQ:ANAB) , Acceleron Pharma Inc. (NASDAQ:XLRN) , Spectranetics Corp. (The) (NASDAQ:SPNC) , and Dermira, Inc. (8-0)

Acceleron's Unique Pipeline Looks Undervalued

2017-10-12 seekingalpha
It has been over two years since I wrote Acceleron Pharma (XLRN) Has Two Potential Blockbusters, so an update is in order. Back then, on July 22, 2015, Acceleron closed at $32.18. It has been very volatile in the meantime, hitting $50.49 on December 29, 2015, but also $21.99 on October 13, 2015. That is part of the thrill (or opportunity, or danger) of investing in clinical-state biotechnology companies. (56-0)

Opaleye Management Inc. - Current Holdings - Fintel.io

2017-10-06 fintel.io
Opaleye Management Inc. has disclosed 41 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 169,717,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Opaleye Management Inc.'s top holdings are Blueprint Medicines Corporation (NASDAQ:BPMC) , AxoGen, Inc. (NASDAQ:AXGN) , FibroGen, Inc. (NASDAQ:FGEN) , Loxo Oncology, Inc. (85-1)

BRIEF-Acceleron announces pricing of public offering of common stock

2017-09-21 reuters
* Acceleron Pharma - Announced underwritten public offering of 5.4 million shares of common stock at a price to public of $37 per share Source text for Eikon: Further company coverage: (2-1)

Lightstone Ventures Closes New Life Sciences Fund at $250 Million

2017-09-20 biospace
MENLO PARK, Calif. and BOSTON, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lightstone Ventures (LSV), a leading global venture capital firm, today announced it has raised $250 million for Lightstone Ventures II, L.P. (LSV II). The firm also announced that it has named Jason Lettmann as a General Partner, and Mark Deem and Hanson Gifford as Partners. (51-0)

BRIEF-Acceleron announces proposed public offering of common stock

2017-09-19 reuters
* Acceleron Pharma Inc - Announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock (2-0)

Acceleron Pharma (XLRN) R&D Day - Slideshow

2017-09-19 seekingalpha
(2-0)

Acceleron Pharma (XLRN) R&D Day - Slideshow

2017-09-19 seekingalpha
(2-0)

Acceleron Pharma's (XLRN) CEO Habib Dable on Q2 2017 Results - Earnings Call Transcript

2017-08-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the Acceleron Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference is being recorded.

Acceleron Pharma Inc. 2017 Q2 - Results - Earnings Call Slides

2017-08-04 seekingalpha
The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2017 Q2 earnings call.

3 Reasons the Best Is Yet to Come for Celgene

2017-08-03 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

CUSIP: 00434H108